Ascent Therapeutics Achieves Preclinical in vivo Proof-of-Principle with Novel Pepducin(TM) GPCR Modulator Platform and Strengthens Senior Management Team

Published: Sep 11, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin™ projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target. The Company also announced that Kenneth Carlson, PhD has joined the senior management team as Senior Director, Head of Biology and that the Company will be presenting at multiple business development events in the coming months.

Back to news